Acquired antithrombin III deficiency – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acquired antithrombin III deficiency – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Antithrombin III Human for Patients with Heparin Resistance Undergoing Cardiac Surgery with Cardiopulmonary Bypass https://clinicaltrials.eu/trial/study-on-antithrombin-iii-human-for-patients-with-heparin-resistance-undergoing-cardiac-surgery-with-cardiopulmonary-bypass/ Wed, 29 Apr 2026 15:01:07 +0000 https://clinicaltrials.eu/trial/study-on-antithrombin-iii-human-for-patients-with-heparin-resistance-undergoing-cardiac-surgery-with-cardiopulmonary-bypass/ This clinical trial is focused on patients who have a condition known as Heparin Resistance, which is a type of Acquired Antithrombin Deficiency. This condition can occur in patients who are scheduled to undergo heart surgery that requires the use of a heart-lung machine, also known as cardiopulmonary bypass. The study is testing a treatment called Atenativ, which is derived from human plasma and contains a substance called Antithrombin III. This treatment is being compared to a placebo to see if it can help patients respond better to heparin, a medication used to prevent blood clots during surgery.

The purpose of the study is to evaluate how effective Atenativ is in helping patients who do not respond well to heparin. Participants in the study will receive either Atenativ or a placebo before their surgery. The study will monitor how well the treatment works in maintaining the patients’ response to heparin during the surgery. The study will also look at the safety of Atenativ and any side effects that may occur.

Throughout the study, participants will be closely monitored by medical professionals. The study will involve several visits and follow-ups to ensure the safety and well-being of the participants. The results of this study could provide valuable information on the use of Atenativ in patients with heparin resistance undergoing heart surgery.

]]>